Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma

Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality

(2015) A. McIntyre et al.   EMBO Molecular Medicine

Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2

(2015) Doruk Keskin et al.   Cell Reports

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 

(2014) B. Escudier et al.   ANNALS OF ONCOLOGY

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

(2014) L del Puerto-Nevado et al.   BRITISH JOURNAL OF CANCER

Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth

(2014) Kshitij Srivastava et al.   CANCER CELL

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

(2014) Robert J. Motzer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Blocking Lipid Synthesis Overcomes Tumor Regrowth and Metastasis after Antiangiogenic Therapy Withdrawal

(2014) Nor Eddine Sounni et al.   Cell Metabolism

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

(2014) Marco Gerlinger et al.   NATURE GENETICS

The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma

(2014) Xiaoen Wang et al.   Translational Oncology

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

(2014) Nicolò Rigamonti et al.   Cell Reports

Clinical biomarkers of response in advanced renal cell carcinoma

(2013) A. Ravaud et al.   ANNALS OF ONCOLOGY

Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma

(2013) Bishoy A. Gayed et al.   BJU INTERNATIONAL

Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy

(2013) D. Gerald et al.   CANCER RESEARCH

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

(2013) K. Sharpe et al.   CLINICAL CANCER RESEARCH

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

Angiopoietin signaling in the vasculature

(2013) Lauri Eklund et al.   EXPERIMENTAL CELL RESEARCH

Integrated molecular analysis of clear-cell renal cell carcinoma

(2013) Yusuke Sato et al.   NATURE GENETICS

Expression of Angiopoietin-2 and Vascular Endothelial Growth Factor Receptor-3 Correlates with Lymphangiogenesis and Angiogenesis and Affects Survival of Oral Squamous Cell Carcinoma

(2013) Chao Li et al.   PLoS One

Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

(2013) Juana Dornbusch et al.   PLoS One

Biomarkers of renal cell carcinoma

(2013) Tin C. Ngo et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Angiopoietins in angiogenesis

(2012) Ernesta Fagiani et al.   CANCER LETTERS

Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

(2012) C. Daly et al.   CANCER RESEARCH

Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria

(2012) Andrea L. Conroy et al.   CRITICAL CARE MEDICINE

Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis

(2012) Tanja Holopainen et al.   JNCI-Journal of the National Cancer Institute

Developmental and Pathological Angiogenesis

(2011) Alicia S. Chung et al.   Annual Review of Cell and Developmental Biology

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials

(2011) Chris Coppin et al.   BJU INTERNATIONAL

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy

(2011) Camillo Porta et al.   BMC CANCER

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma

(2011) Jonas Busch et al.   BMC CANCER

Sunitinib and other targeted therapies for renal cell carcinoma

(2011) T Powles et al.   BRITISH JOURNAL OF CANCER

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

(2010) V Goede et al.   BRITISH JOURNAL OF CANCER

Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth

(2010) H. Hashizume et al.   CANCER RESEARCH

Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

(2009) I. Helfrich et al.   CLINICAL CANCER RESEARCH

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal cell carcinoma

(2009) Brian I Rini et al.   LANCET